2394 Sodium-glucose transporter 2 is a novel diagnostic and therapeutic target for early-stage lung adenocarcinoma
OBJECTIVES/SPECIFIC AIMS: Lung cancer claims 160,000 lives in the United States every year, and lung adenocarcinoma (LADC) is the most frequent type. Early diagnosis is crucial. Computed tomography (CT) is very sensitive in identifying early-stage lung nodules, but has low specificity. Increased glu...
Main Authors: | Claudio Scafoglio, Gihad Abdelhady, Jie Liu, Jane Yanagawa, Dean Wallace, Jorge Barrio, Steven Dubinett, David Shackelford |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2018-06-01
|
Series: | Journal of Clinical and Translational Science |
Online Access: | https://www.cambridge.org/core/product/identifier/S205986611800122X/type/journal_article |
Similar Items
-
PB2394: PTPRJ AS A ROBUST DIFFERENTIATING MARKER IN MANTLE CELL LYMPHOMA
by: Simone Valentin Hansen, et al.
Published: (2023-08-01) -
Heterogeneity of Glucose Transport in Lung Cancer
by: Cesar A. Martinez, et al.
Published: (2020-06-01) -
First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers
by: Fei Tang, et al.
Published: (2023-09-01) -
Metabolic signatures in pancreatic ductal adenocarcinoma: diagnostic and therapeutic implications
by: Ruining Gong, et al.
Published: (2023-12-01) -
Sodium phosphate solution as bowel preparation for outpatient diagnostic and therapeutic manipulations
by: N. V. Topchy, et al.
Published: (2017-12-01)